Non-induced leukocyte extract reduces HIV replication and TNF secretion

Biochemical and Biophysical Research Communications

Volumn 325, Issue 3, 2004, Pages 1075-1081

  Fernández Ortega, Celia ^a   Dubed, Marta ^b   Ramos, Yudith ^a   Navea, Leonor ^b   Álvarez, Giselle ^b   Lobaina, Leonor ^b   López, Lissette ^a   Casillas, Dionne ^a   Rodríguez, Licet ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Laboratory for AIDS Research   (Cuba)

Author keywords

Dialyzable leukocyte extract; HIV; Inflammation; LPS; MT4 cells; Sendai virus; TNF; Transfer factor

Indexed keywords

LEUKOCYTE EXTRACT; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; LEUKOCYTE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SECRETION; SENDAI VIRUS; VIRUS INDUCTION; VIRUS REPLICATION;

BLOOD CELLS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HIV-1; HUMANS; LIPOPOLYSACCHARIDES; MALE; T-LYMPHOCYTES; TRANSFER FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

SENDAI VIRUS;

EID: 8444230034     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.10.142     Document Type: Article

References (45)

1. The World Health Report 2004: Changing history, World Health Organization (2004) 5-13
2. A. Kinter, J. Arthos, C. Cicala, and A.S. Fauci Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis Immunol. Rev. 177 2000 88 98
3. O. Cohen, A. Kinter, and A. Fauci Host factors in the pathogenesis of HIV infection Immunol. Rev. 159 1997 31 48
4. H. Mudiyanselage, T. Herath, Y. Takano-Ishikawa, and K. Yamaki Inhibitory effect of some flavonoids on tumor necrosis factor-alpha production in lipopolysaccharide-stimulated mouse macrophage cell line J774.1 J. Med. Food 6 4 2003 365 370
5. P. Aukrust, F. Muller, E. Lien, I. Nordoy, N. Liabakk, D. Kvale, T. Espevik, and S. Froland Tumor necrosis actor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure J. Infect. Dis. 179 1999 74 82
6. M.P. D'Souza, S. Cairns, and S.F. Plaeger Current evidence and future directions for targeting HIV entry. Therapeutic and prophylactic strategies JAMA 284 2000 215 222
7. C. Hoffman Tratamiento contra el VIH 2003 C. Hoffmann B. Kamps HIV Medicine 2003 2003 Flying Publisher Paris 41 47
8. H. Lawrence The transfer in human of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes J. Clin. Invest. 34 1955 219 224
9. H.H Fudenberg, and H.H. Fudenberg Transfer factor: past, present and future H. Baolai W. Ruzhang Z. Zhaofen Research and Application of Transfer Factor and DLE 1989 Xueyuan Press Beijing 557 604
10. V. Rosso di San Secondo, A. Aniasi, and G. Piccolo Influence of DLE-extracted lymphocytic suppressor factor on CSA-induced immunosuppression Biotherapy 9 1996 159 162
11. M. Blume, E. Rosenbaum, R. Cohen, J. Gershow, A. Glassberg, and E. Shepley Adjuvant immunotherapy of high risk stage I melanoma with transfer factor Cancer 47 1981 882 888
12. V. Prasad, G. Pizza, C. De Vinci, and D. Viza Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study Biotherapy 9 1996 109 115
13. R. Cabezas, S. Estrada, L. Padierna, C. Fernández-Ortega, and P. López Inmunoterapia con Factor de Transferencia en pacientes con herpes zoster BiotecnologIÍa Aplicada 7 1990 52 57
14. S. Estrada, A. Nayaga, and E. Serrano Comparative study of Transfer Factor and Aciclovir in the treatment of herpes zoster Int. J. Immunopharm. 20 1998 521 535
15. O. Delgado, E.L. Romero, E. Belfort, F. Pifano, J.V. Scorza, and Z. Rojas Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis Clin. Immunol. Immunopathol. 19 3 1981 351 359
16. J. Costello The effect of transfer factor on neutrophil function in chronic mucocutaneus candidiasis Br. J. Haematol. 33 1976 132
17. S. Estrada, and O. Velasco Inmunoterapia de la tuberculosis pulmonar avanzada con factor de transferencia especIÍfico Salud Pública de México 6 1983 589 600
18. A. Arnaudov, and N. Tziporkov Some properties and protective activity of specific DLE against Salmonella cholerae suis infection Biotherapy 9 1996 105 108
19. A. McMeeking, W. Borkowsky, P.H. Klesius, R.S. Holzman, and H.S. Lawrence A controlled trial of bovine dialyzable leucocyte extract for cryptosporidiosis in patients with AIDS J. Infect. Dis. 161 1990 108 112
20. A. Gottlieb, M. Sizemore, M. Gottlieb, and C. Kern Rationale and clinical results of using leukocyte-derived immunosupportive therapies in HIV disease Biotherapy 9 1995 27 31
21. G. Pizza, F. Chiodo, V. Colangeli, F. Gritti, E. Raise, H. Fudenberg, C. De Vinci, and D. Viza Preliminary observations using HIV-specific transfer factor in AIDS Biotherapy 9 1996 41 47
22. J. Rivero, A. Miró, M. Rosario, and P. López Efecto del IFN-alpha o del Factor de Transferencia en la supervivencia de individuos asintomáticos infectados por el VIH BiotecnologIÍacute a Aplicada 12 3 1995 161 162
23. C. Fernández-Ortega, M. Dubed, O. Ruibal, O. Vilarrubia, J. MenéndezdeSan Pedro, L. Navea, M. Ojeda, and M. Araña Inhibition of in vitro HIV infection by dialyzable leukocyte extract Biotherapy 9 1996 33 40
24. M. Ojeda, C. Fernández-Ortega, and M. Araña Dialyzable leukocyte extract (DLE) reduces lipopolysaccharide-induced tumor necrosis factor secretion in human leukocytes Biotherapy 9 1996 163 170
25. M. Ojeda, C. Valenzuela, M. Araña, and C. Fernández-Ortega TNFα production in whole blood cultures from healthy individuals Biochem. Biophys. Res. Commun. 292 2002 538 541
26. J. Larrick, M. Hirata, H. Zheng, J. Zhong, D. Bolin, J. Cavaillon, H. Warren, and S. Wright A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity J. Immunol. 152 1994 231 236
27. E. Ross, A. Buckler-White, A. Rabson, G. Englund, and M. Martin Contribution of NFκB and Sp1 binding motifs to the replicative capacity of Human Immunodeficiency Virus type 1: distinct patterns of viral growth are determined by T-cell types J. Virol. 65 1991 4350 4358
28. A. Fauci Infectious diseases: considerations for the 21st century Clin. Infect. Dis. 32 2001 675 685
29. AIDS epidemic update, Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO) (2003). Available from: 〈http://www. uniads.org〉
30. N. Saksen, and S. Potter Reservoirs of HIV-1 in vivo: Implications for antiretroviral therapy AIDS Rev. 5 2003 3 18
31. J. Newcomb-Fernandez HIV treatment interruptions: a review Res. Initiat. Treat. Action 9 2003 5 13
32. H. Binswanger HIV/AIDS treatment for millions Science 292 2001 221 223
33. A. Fauci The AIDS epidemic: considerations for the 21st century N. Engl. J. Med. 341 1999 1046 1050
34. B. Lane, D. Markovitz, N. Woodford, R. Rochford, R. Strieter, and M. Coffey TNFα inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor (CCR5) expression J. Immunol. 163 1999 3653 3661
35. V. Quivy, E. Adam, Y. Collette, D. Demonte, A. Chariot, C. Vanhulle, B. Berkhout, R. Castellano, Y. Launoit, A. Burny, J. Piette, V. Bours, and C. Van Lin Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-κB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies J. Virol. 76 2002 11091 11103
36. K. Hestdal, P. Aurkrust, F. Muller, E. Lien, V. Bjerkeli, T. Espevik, and S. Froland Dysregulation of membrane-bound Tumor necrosis factor receptors on mononuclear cells in human Immunodeficiency Virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load Blood 90 1997 2670 2679
37. M. Ojeda, C. Fernández-Ortega, and M. Araña Dialyzable leukocyte extract (DLE) suppress in unstimulated MT4 cells the activity of essential transcription factors for HIV-1 gene expression Biochem. Biophys. Res. Commun. 273 2000 1099 1103
38. N. Kobayashi, Y. Hamamoto, and N. Yamamoto Production of tumor necrosis factor by T cell lines infected with HTLV-1 may cause their high susceptibility to human immunodeficiency virus infection Med. Microbiol. 179 1990 115 122
39. H. Lin, S. Chu, D. Wang, and N. Feng Pharmacological modulation of TNF production in macrophages J. Microbiol. Immunol. Infect. 37 2004 8 15
40. J. Lokaj, J. Pekárek, and P. KuklIÍnek Dialyzable leukocyte extract in the therapy of sepsis V. Mayer J. Borvak Leukocyte Dialyzates and Transfer Factor 1987 SAC Press Bratislava 516 525
41. A. Haziot, B.Z. Tsuberi, and S. Goyert Neutrophil CD14: biochemical properties and role in the secretion of TNF-α in response to lipopolysaccharide J. Immunol. 150 1993 5556 5565
42. J. Cho, J. Park, P. Kim, S. Chae, E. Yoo, K. Baik, J. Lee, and M. Park Inhibitory effect of oriental herbal medicines on tumor necrosis factor-α production in lipopolysaccharide-stimulated RAW264.7 cells Nat. Prod. Sci. 5 1999 12 19
43. J. Cho, J. Park, P. Kim, E. Yoo, K. Baik, and M. Park Savinin, a lignan from Pterocarpus santalinus inhibits tumor necrosis factor-α production and T-cell proliferation Biol. Pharm. Bull. 24 2001 167 171
44. C. Zuany-Amorim, C. Manlius, I. Dalum, M. Jensen, A. Gautan, G. Pay, S. Mouritsen, and C. Walker Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergies diseases Int. Arch. Allergy Immunol. 133 2004 154 163
45. J. Cho, J. Park, E. Yoo, K. Baik, J. Jung, J. Lee, and M. Park Inhibitory effect of sesquiterpene lactones from Saussurea lappa on tumor necrosis factor-α production in murine macrophage-like cells Plant Med. 64 1998 594 597